Chemical formula: C₁₇H₁₁N₅ Molecular mass: 285.303 g/mol PubChem compound: 3902
Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02BG04 | Letrozole | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BG Aromatase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LETROZOLE / GLENMARK Film-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Letrozole is an active ingredient of these brands:
United States (US)Canada (CA)Finland (FI)Germany (DE)Israel (IL)Japan (JP)Malta (MT)Mexico (MX)New Zealand (NZ)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
